Latest News & Features
Americas
Danish multinational asks Delaware court to block semaglutide generics from Sun Pharma and Mylan | ANDAs infringe two claims of patent granted in July, Novo claims. 11 September 2024
Careers
CRISPR expert with two decades of experience in biotechnology and life sciences, joins HLK as a partner | Latest addition previously held leadership roles at Murgitroyd and HGF | Partner will be attending LSPN North America Fall 2024 in San Francisco. 10 September 2024
Unified Patent Court
UPC clarifies that evidence must show that pre-launch preparations are complete for threat of imminent infringement to occur | Question remains over how the UPC will deal with the cumulative activities of several companies in a group | Court also broaches key cross-border question. 9 September 2024
Americas
AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews. 5 September 2024
Careers
Firm adds pair to its Washington DC office | Both bring experience in patent counselling and IP transactions | Expertise in biotech, life sciences, pharmaceutical sectors, consumer products, biomedical, chemical, food science, agriculture, and medical devices. 5 September 2024
Unified Patent Court
A distinctive UPC approach to patent validity and revocations is emerging as the court shows its willingness to break new ground, say Emily Bottle and Sebastian Moore of HSF. 5 September 2024
Unified Patent Court
The Unified Patent Court’s first decisions from the first instance divisions—with healthcare-related subject matter predominating—have been made within weeks of the first anniversary of the UPC opening for litigation cases. Darren Smyth of EIP examines the details. 3 September 2024
Careers
Firm welcomes veteran litigator from Baker McKenzie and transactional lawyer from Covington & Burling | Pair specialise in global IP litigation and strategic transactions. 3 September 2024
Europe
Court grants access to test case documents after eight months | Mathys & Squire applied for access to challenge UPC's transparency | Firm says "significant concerns" remain about the court's commitment to transparency and open justice. 30 August 2024
Americas
Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed. 29 August 2024